Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
Plos One
|
August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
Donna M Evon, Paul W Stewart, Jipcy Amador, et al.
Journal of Hepatology
|
January 1, 2020
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)"
Donna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study
Marina Serper, Donna M Evon, Jipcy Amador, et al.
Journal of Clinical Gastroenterology
|
November 24, 2020
WGO Guidance for the Care of Patients With COVID-19 and Liver Disease
Saeed Hamid, Mario R Alvares da Silva, Kelly W Burak, et al.
Hepatology (Baltimore, Md.)
|
April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau, Paul Y Kwo, Susan Rhee, et al.
Gastroenterology
|
August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Eric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 2, 2025
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Luis Antonio Diaz, Veeral Ajmera, Juan Pablo Arab, et al.
The New England Journal of Medicine
|
November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
Plos One
|
August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
Donna M Evon, Paul W Stewart, Jipcy Amador, et al.
Journal of Hepatology
|
January 1, 2020
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)"
Donna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study
Marina Serper, Donna M Evon, Jipcy Amador, et al.
Journal of Clinical Gastroenterology
|
November 24, 2020
WGO Guidance for the Care of Patients With COVID-19 and Liver Disease
Saeed Hamid, Mario R Alvares da Silva, Kelly W Burak, et al.
Hepatology (Baltimore, Md.)
|
April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau, Paul Y Kwo, Susan Rhee, et al.
Gastroenterology
|
August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Eric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 2, 2025
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Luis Antonio Diaz, Veeral Ajmera, Juan Pablo Arab, et al.
The New England Journal of Medicine
|
November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Page
of 10